Late-Breaking Research: Clinical Research 4

• LB412 · PDF Reprogramming immunity: Personalized T cell approaches in gastric cancer Giulia Milardi, Andrea Pansa, Fabio Marchianò, Silvia Erratico, Miriam Cieri, Giovanni Garbarino, Luigi Maria Terracciano, Rita Alfieri, Silvia Basato, Alberto Puccini, Alessandro Repici, Cesare Hassan, Charlotte Ng, Chiara Cattaneo, Carlo Castoro, Salvatore Piscuoglio
• LB413 · PDF Peripheral blood as the sole source for cancer neoantigen and reactive T cell discovery Andrea Garcia Garijo, Immaculada Creus-González, Pierre Levy, Ana Belen Moreno-Cárdenas, Maria Lozano-Rabella, Carlos Alberto Fajardo, Ricardo Pujol-Borrell, Albert Marín, Johanna Kusnick, Jared Gartner, Anna Yuste-Estevanez, Alma Calahorro, Jose Fernandez, Rebeca Sanz, Thomas B. K. Watkins, Vladimir Galvao, Eva Muñoz-Couselo, Javier Ros, Elena Elez, Mafalfa Oliveira, Cristina Saura, Irene Braña, Ana Oaknin, Ramon Alemany, Josep Tabernero, Raquel Perez-Lopez, Alexander M. Frankell, Elena Garralda, Rodrigo De Almeida Toledo, Alena Gros
• LB414 · PDF Updated clinical efficacy and translational biomarker analysis of tumor infiltrating lymphocyte therapy (LM103) in metastatic melanoma Chuanliang Cui, Li Zhou, Yan Kong, Xuan Wang, Yue Yang, Jiayong Liu, Zhichao Tan, Zhihong Chi, Lu Si, Bin Lian, Lili Mao, Hui Tian, Yuan Yuan, Yongming Xue, Jun Guo
• LB415 · PDF Nanobody:STING agonists reprogram the tumor microenvironment and improve adoptive cell therapy for solid tumors Neil C. Chada, Alexandra E. Lee, Hailey Jane Frank, Dawn K. Oh, Hannah Ki, Alexander J. Kwiatkowski, Karan Arora, John T. Wilson
• LB416 · PDF Targeting XPO1 reprograms immune microenvironment and confers sensitivity to immune checkpoint blockade in pancreatic ductal adenocarcinoma Md Hafiz Uddin, Mohammed Najeeb Al Hallack, Misako Nagasaka, Sahar F. Bannoura, Husain Y. Khan, Amro Aboukameel, Fulya K. Alkan, Hilmi K. Alkan, Khalil Choucair, M Wasif Saif, Bin Bao, Ibrahim Azar, Eliza W. Beal, Miguel Tobon, Steve Kim, Amr Mohamed, Gregory Dyson, Rafic Beydoun, Ramzi M. Mohammad, Herbert Chen, Bassel El-Rayes F. El-Rayes, Philip A. Philip, Boris C. Pasche, Hasan Korkaya, Asfar S. Azmi
• LB417 · PDF Reprogramming anti-tumor immunity through therapeutic antagonism of the mSWI SNF chromatin remodeling complex Fan Yang, Yi Bao, Lanbo Xiao, Yuanyuan Qiao, Weiping Zou, Arul M. Chinnaiyan
• LB418 · PDF RELATIVITY-104 Part 2: translational analyses in the programmed death ligand 1 (PD-L1) ≥ 1% and non-squamous (NSQ) non-small cell lung cancer (NSCLC) subgroup Jaclyn Neely, Annie Yu, Nicolas Girard, Manuel Cobo-Dols, Mauricio Burotto, Luis Paz-Ares, Vamsidhar Velcheti, Martin Reck, Srijata Samanta, Anila Qureshi, Priyanka Kasbekar, Charlie Garnett-Benson
• LB419 · PDF Dose escalation and expansion of nivolumab plus relatlimab (NIVO + RELA) in solid tumors in RELATIVITY 020 Parts A-C Paolo A. Ascierto, Carlo Gomez-Roca, Ignacio Melero, Katriina Jalkanen, Rachel E. Sanborn, Juan Martin-Liberal, James Larkin, Rastilav Bahleda, F. Stephen Hodi, Margaret Callahan, Marta Nykas, Giuseppe Curigliano, Sebastian Bauer, Solange Peters, Takekazu Aoyama, Mark Semaan, Sourav Mukherjee, Sonia Dolfi, Satyendra Suryawanshi, Evan Lipson
• LB420 · PDF SAAL1: A novel biomarker for predicting and therapeutic target for overcoming immunotherapy resistance in esophageal squamous cell carcinoma Caiyan Fang, Fujin Shi, Zhiyi Zhang, Hong Yang
• LB421 · PDF Extracorporeal photopheresis vs. systemic immunosuppression for treatment of immune-related adverse events: Final analysis of the prospective two-arm PRIA study Lisa Wein, Carolin Ertl, Theresa Ruf, Monika Morak, Ying Wang, Christina Schmitt, Xiomara Garza Vazquez, Valerie Glatzel, Richard David-Rus, Mohammed Mitwalli, Jerome Srour, Pia Schöpf, Dirk Tomsitz, Lars E. French, Lucie Heinzerling
• LB422 · PDF Clinical value of immune checkpoints in pancreatic ductal adenocarcinomaco-overexpressing with CEACAM6 Daruka Mahadevan, Chenbo Sun, Yuliang Chen, Aisha Al-Khinji, Ritu Pandey
• LB423 · PDF Invigorating pre-existing tumor-infiltrating expandable (TIE) T cell clonotypes in exceptional responders with dual PARP-PD-1 blockade in homologous recombination deficient (HRD) pancreatic cancer Marc Hilmi, Wilson Mckerrow, Joshua D. Schoenfeld, Shigeaki Umeda, Nuray Tezcan, Catherine O'Connor, Yuval Elhanati, Charlotte Reiche, Martina Milighetti, Mara Sherman, Elias-Ramzey Karnoub, Roshan Sharma, Vincenzo Nasca, Kevin Soares, Zeynep Tarcan, Jerry Melchor, Olca Basturk, Nadeem Riaz, Nicolas Lecomte, Vinod P. Balachandran, Dana Pe’er, Benjamin D. Greenbaum, Christine A. Iacobuzio-Donahue, Eileen M. O'Reilly, Wungki Park
• LB424 · PDF GZMA+ CD8+ T cells underlie the pathological complete response of BRCA-mutated breast cancers to neoadjuvant PARPi plus anti-PD-1 therapy Songhan Li, Bo Liu, Fei Xie, Yuan Peng, Shu Wang, Hai Qi
• LB425 LB425 Search for targets of anti-cancer immunity in patients receiving an off-the-shelf cancer's dark matter vaccine, DPV-001, combined with anti-PD-1 +/- anti-GITR in head and neck squamous cell cancer (HNSCC) Traci Hilton, Ryan Meng, Guo Hui Gan, Tarsem Moudgil, Christopher Paustian, Noah Simons, Venkatesh Rajamanickam, Shawn M. Jensen, Elie Adwani, Sierra J. Smith, Matthew H. Taylor, Olivier Fesneau, Thomas M. Duhen, Irene Shih, Myungkyu Jang, Annie Long, Abigail Staeck, Tijana Jovanovic, Brady Bernard, Christie Tanisha, Noriko Iwamoto, Yuriko Minegishi, Koji Ueda, William L. Redmod, Lessli M. Rushforth, Takashi Shimada, Patrick Rethwisch, Carlo B. Bifulco, Hong-ming Hu, Walter J. Urba, Yoshinobu Koguchi, Marcus A. Couey, Richard B. Bell, Jianguo Huang, Eric Tran, Brian Piening, Rom Leidner, Bernard A. Fox
• LB426 · PDF Blockade of tumor-intrinsic TGF-beta signaling drives hyperprogression in small cell lung cancer Anish Thomas, Brett Schroeder, Chirayu Mohindroo, Anna-Lena Meinhardt, Nobuyuki Takahashi, Rajesh Kumar, Yang Zhang, Ajit Kumar Sharma
• LB427 · PDF Humanized PDX models uncover drug-reversible epigenetic immune exclusion governing T-cell therapy response in DLBCL, captured in patients by EPICORE stratifier Giovanni Medico, Giorgia Zanetti, Giorgio Bertolazzi, Francesco Vallania, Paul Zumbo, Maider Amiama, Doron Betel, Maria Cacciapuoti, Abigail Taylor, Clarisse Kayembe, Sanjay Patel, Arvin Ruiz, Jennifer Ziello, Jason Weirather, Gulpreet Kaur, Luca Cappelli, Luca Paruzzo, Marco Ruella, Zhenyuan Dong, Larry Kwak, Nicolás Di Siervi, Maria Revuelta, Claudio Tripodo, Leandro Cerchietti, Giorgio Inghirami
• LB428 · PDF Targeting EZH2 to overcome immunotherapy resistance in mCRPC unlocks NSD2-dependent tumor vulnerabilities Pilar Salamanca Jiménez, Inés Gonzalez-Vazquez, Roderic Espin, Nadia Garcia, Lidia Franco, MA Pujana, JM Piulats, Alvaro Aytes
• LB429 · PDF Impact of severe liver metastases on clinical response to immunotherapy in solid tumors Jibran Ahmed, Bettzy Stephen, Evan Kwiatkowski, Marcus R. Anderson, Mohamed H. Derbala, Israa Salih, Lilibeth Castillo, Yali Yang, Serdar A. Gurses, Hao Yan, Joann T. Lim, Albert R. Klekers, Hung Le, Lei Kang, Mingxuan Xu, Harold N. Tan, Stephane Champiat, Tin-Yun Tang, Ecaterina E. Dumbrava, Sarina A. Piha-Paul, Jordi Rodon Ahnert, Apostolia M. Tsimberidou, Timothy A. Yap, Siqing Fu, David S. Hong, Funda Meric-Bernstam, Priya R. Bhosale, Aung Naing

在会议检索中浏览本分会场